GLSI

Greenwich Lifesciences Inc

GLSI, USA

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

https://greenwichlifesciences.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GLSI
stock
GLSI

What is Noble Financial’s Estimate for GLSI FY2025 Earnings? Defense World

Read more →
GLSI
stock
GLSI

Noble Financial Issues Pessimistic Outlook for GLSI Earnings MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$45

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

66.99

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-190.02 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-109.06 %

Low 2%

High 10%

Debt to Equity

-

Low

0.74

Low 1

High 0.3

Investors

* Institutions hold a combined 15.09% of the total shares of Greenwich Lifesciences Inc

1.

BlackRock Inc

(2.6939%)

since

2025/06/30

2.

Vanguard Group Inc

(1.9736%)

since

2025/06/30

3.

iShares Russell 2000 ETF

(1.1378%)

since

2025/08/31

4.

Vanguard Total Stock Mkt Idx Inv

(1.1018%)

since

2025/07/31

5.

Geode Capital Management, LLC

(1.0197%)

since

2025/06/30

6.

Crédit Agricole S.A.

(0.6383%)

since

2025/03/31

7.

PV BUYBACK USA Classe B USD

(0.6383%)

since

2025/03/31

8.

Northern Trust Corp

(0.6073%)

since

2025/06/30

9.

State Street Corp

(0.6034%)

since

2025/06/30

10.

Fidelity Small Cap Index

(0.4483%)

since

2025/06/30

11.

Marshall Wace Asset Management Ltd

(0.4119%)

since

2025/06/30

12.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4014%)

since

2025/07/31

13.

iShares Russell 2000 Growth ETF

(0.3532%)

since

2025/08/31

14.

Millennium Management LLC

(0.2508%)

since

2025/06/30

15.

Fidelity Extended Market Index

(0.2276%)

since

2025/07/31

16.

Vanguard Russell 2000 ETF

(0.2138%)

since

2025/07/31

17.

State St Russell Sm Cap® Indx SL Cl I

(0.2091%)

since

2025/08/31

18.

Renaissance Technologies Corp

(0.2003%)

since

2025/06/30

19.

STRS OHIO

(0.1467%)

since

2025/06/30

20.

Charles Schwab Investment Management Inc

(0.1398%)

since

2025/06/30

21.

HighTower Advisors, LLC

(0.1245%)

since

2025/06/30

22.

Goldman Sachs Group Inc

(0.121%)

since

2025/06/30

23.

Schwab Small Cap Index

(0.1195%)

since

2025/07/31

24.

NT R2000 Index Fund - NL

(0.1143%)

since

2025/06/30

25.

Bank of New York Mellon Corp

(0.1071%)

since

2025/06/30

26.

Citadel Advisors Llc

(0.101%)

since

2025/06/30

27.

iShares Micro-Cap ETF

(0.0996%)

since

2025/08/31

28.

NT R2000 Index Fund - DC - NL - 3

(0.0911%)

since

2025/06/30

29.

iShares Russell 2000 Small-Cap Idx Instl

(0.0873%)

since

2025/07/31

30.

Morgan Stanley - Brokerage Accounts

(0.0863%)

since

2025/06/30

31.

Fidelity Total Market Index

(0.0777%)

since

2025/07/31

32.

Barclays PLC

(0.0776%)

since

2025/06/30

33.

Extended Equity Market Fund K

(0.0758%)

since

2025/06/30

34.

Russell 2500™ Index Fund F

(0.0659%)

since

2025/06/30

35.

Rhumbline Advisers

(0.0658%)

since

2025/06/30

36.

Nuveen Small Cap Blend Idx R6

(0.0596%)

since

2025/07/31

37.

Goldman Sachs Absolute Ret Trckr Instl

(0.0595%)

since

2025/06/30

38.

Fidelity Series Total Market Index

(0.0563%)

since

2025/07/31

39.

New York State Common Retirement Fund

(0.044%)

since

2025/06/30

40.

Bank of America Corp

(0.0384%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.3

EPS Estimate

-0.23

EPS Difference

-0.07

Surprise Percent

-30.4348%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.